| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/29/2004 | US20040146929 for drug screening, in vitro or in vivo diagnosis, and gene therapy; antitumor agents; genetic engineering; kits |
| 07/29/2004 | US20040146888 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 07/29/2004 | US20040146882 Human acid sensing ion channel 2b (hASIC2b), process for producing the same, and its use |
| 07/29/2004 | US20040146872 Comprises nucleotide sequences coding delta-2-enoyl-coA isomerase for use in identifying modulators for treatment and diagnosis of inflammatory, cardiovascular, skin, body weight and cancer disorders |
| 07/29/2004 | US20040146853 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 07/29/2004 | US20040146591 Solvent extraction, mixing with aqueous solution; drying; sterilization; drugs, food; aging resistance, cognition activators , brain disorders; incontinence; Alzheimer's disease, autism, Parkinson's disease, antiarthritic agents |
| 07/29/2004 | US20040146549 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 07/29/2004 | US20040146547 Disposal system for transdermal dosage form |
| 07/29/2004 | US20040146532 Agents and methods for treating pain |
| 07/29/2004 | US20040146508 Use of cd25 binding molecules in steroid-resistant patients |
| 07/29/2004 | US20040146495 Analyzing a blood sample for secretin level |
| 07/29/2004 | US20040146468 With excipient; suppress or reduce the gustatory function, in particular as regards a bitter and/or sweet and/or acid taste |
| 07/29/2004 | DE10303671A1 New 8alpha,14beta-dialkyl-18-nor steroids useful as pharmaceuticals, intermediates or carriers for treating e.g. tumors, alzheimers disease |
| 07/29/2004 | DE10303667A1 New 14-fluoro-15,17-dihydroxysteroid derivatives, useful for treating Alzheimer's disease and tumors, and as intermediates, are e.g. inhibitors of steroid dehydrogenase |
| 07/29/2004 | DE10301917A1 Use of porphyrin precursors for photodynamic therapy of psoriasis and inflammatory skin and joint diseases |
| 07/29/2004 | DE10301650A1 New 1-phenyl-2-aminomethylnaphthalene derivatives used for treating tumors, neurodegeneration, inflammation and Chagas disease |
| 07/29/2004 | CA2516398A1 Method of modulating il-6 |
| 07/29/2004 | CA2513042A1 Blood-brain barrier disruption inhibitor |
| 07/29/2004 | CA2512765A1 Therapeutic agent for schizophrenia |
| 07/29/2004 | CA2512673A1 2-o sulfatase compositions and related methods |
| 07/29/2004 | CA2512602A1 Benzoxazole derivatives and their use as adenosine receptor ligands |
| 07/29/2004 | CA2512111A1 Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| 07/29/2004 | CA2511858A1 Metastin derivative and use thereof |
| 07/29/2004 | CA2509251A1 Method of treating cognitive decline due to sleep deprivation and stress |
| 07/29/2004 | CA2507948A1 Aminoindazole derivates and use thereof as kinase inhibitors |
| 07/29/2004 | CA2507945A1 Prevention and treatment of alzheimer's disease |
| 07/28/2004 | EP1441034A1 Methods of evaluating phosphatase inhibitors |
| 07/28/2004 | EP1441033A2 Eukaryotic gene expression cassette based on Herpes simplex virus |
| 07/28/2004 | EP1440980A2 Peptide analogs of human myelin basic protein |
| 07/28/2004 | EP1440976A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/28/2004 | EP1440709A2 Combinations comprising cGMP PDE5 inhibitors. |
| 07/28/2004 | EP1440691A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440690A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440689A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440163A2 Methods and compositions for the treatment and diagnosis of pain disorders using 46566 |
| 07/28/2004 | EP1440157A1 Methods and means for producing proteins with predetermined post-translational modifications |
| 07/28/2004 | EP1440143A1 Device with recessed tracks for forming a cellular network |
| 07/28/2004 | EP1440091A1 Nogo receptor homologues and their use |
| 07/28/2004 | EP1440084A2 Sperm factor sequences |
| 07/28/2004 | EP1440076A1 Silicon compounds |
| 07/28/2004 | EP1440075A1 Novel 3beta-amino azabicyclooctane heteroaromatic amide derivatives, preparation method and therapeutic uses thereof |
| 07/28/2004 | EP1440073A1 Pde9 inhibitors for treating cardiovascular disorders |
| 07/28/2004 | EP1440071A1 Imidazopyridine compounds as 5-ht 4? receptor modulators |
| 07/28/2004 | EP1440062A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 07/28/2004 | EP1440060A1 4(piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders |
| 07/28/2004 | EP1440059A1 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| 07/28/2004 | EP1440057A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 07/28/2004 | EP1440052A1 Benzamide derivatives as antagonists of orexin receptors |
| 07/28/2004 | EP1439878A2 Method and apparatus for dispensing inhalator medicament |
| 07/28/2004 | EP1439863A2 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 07/28/2004 | EP1439838A1 Macrolides containing pharmaceutical compositions |
| 07/28/2004 | EP1439837A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 07/28/2004 | EP1439836A1 Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| 07/28/2004 | EP1439831A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
| 07/28/2004 | EP1439830A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/28/2004 | EP1439829A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient |
| 07/28/2004 | EP1439825A1 Methods of treatment using a gastric retained gabapentin dosage |
| 07/28/2004 | EP1439822A1 Metallothioneine-containing liposomes |
| 07/28/2004 | EP1439819A1 Formulation of an erodible, gastic retentive oral dosage form using in vitro disintegration test data |
| 07/28/2004 | EP1322593B1 O-substituted 6-methyl-tramadol derivatives |
| 07/28/2004 | EP1322592B1 Substituted 1-aminobutan-3-ol derivatives |
| 07/28/2004 | EP1317264B1 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 07/28/2004 | EP1284744B1 Antimigraine combination comprising sapindus and emblica extracts |
| 07/28/2004 | EP1226244B1 Polypeptides with non-natural primary signalling motifs |
| 07/28/2004 | EP1183042B1 Methods for treating diabetes |
| 07/28/2004 | EP1180094B1 Fused polycyclic amino acids as pharmaceutical agents |
| 07/28/2004 | EP1077692B1 Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| 07/28/2004 | EP1009412B1 Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons |
| 07/28/2004 | EP1001761B1 Use of cholinesterase inhibitors for treating attention deficit disorders |
| 07/28/2004 | EP0927183B1 Spirocyclic metalloprotease inhibitors |
| 07/28/2004 | EP0912741B1 T-cell selective interleukin-4 agonists |
| 07/28/2004 | EP0823895B1 Fatty acid esters as bioactive compounds |
| 07/28/2004 | EP0752884B1 Method of treating auto-immune diseases using type one interferons |
| 07/28/2004 | EP0696201B1 Supplemented tissue sealants, methods of their production and use |
| 07/28/2004 | CN1516739A Use of HMG fragments as anti-inflammatory agents |
| 07/28/2004 | CN1516701A (Pyrido/thieno)-[f]-oxazepin-5-one derivatives as AMPA receptor positive regulator |
| 07/28/2004 | CN1516699A Polymorphic forms of 1-4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 07/28/2004 | CN1516693A Benzimidazoles that are useful in treating sexual dysfunction |
| 07/28/2004 | CN1516692A Novel compounds of family of 3-alkyl-(4,5-diphenyl-imidazol-1-yl) and their use as soothing agents |
| 07/28/2004 | CN1516687A 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| 07/28/2004 | CN1516601A Orally deliverable pharmaceutical composition comprising drug of low water solubility (cox-2 inhibitor), solvent, fatty acid and organic amine |
| 07/28/2004 | CN1516587A Quinazoline derivatives capable of promoting release of parathyroid |
| 07/28/2004 | CN1516586A Novel oral general anesthetics and metabolitically resistant anticonvulsants |
| 07/28/2004 | CN1516585A Process for preparing paroxetine HCI which limits formation of pink colored compounds |
| 07/28/2004 | CN1516584A Spiropyrazole compounds |
| 07/28/2004 | CN1516581A Amino-sulfonyl-containing active compound (COX-2 inhibitors), polyethylene glycol and removing free radical antioxidate and liquid |
| 07/28/2004 | CN1516580A Sulfonamides |
| 07/28/2004 | CN1515579A Fatty alcohol glycoside compound-acanthus ilicifolius glycoside C and its application |
| 07/28/2004 | CN1515564A Method for preparing sitaipulan |
| 07/28/2004 | CN1515562A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative |
| 07/28/2004 | CN1515559A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative |
| 07/28/2004 | CN1515554A Intermediate compound for producing 2-amino-6-(2-substituted-4-phenoxy) substituted pyridine compound |
| 07/28/2004 | CN1515551A 1,2-indane or indoline derivative |
| 07/28/2004 | CN1515548A Oxaminic acid used as thyroid gland receptor ligand and its derivative |
| 07/28/2004 | CN1515299A Medicine for curing epilepsy |
| 07/28/2004 | CN1515289A Chinese medicine product with functions of detoxifying in 3 days and eliminating withdrawl syndrome |
| 07/28/2004 | CN1515270A Processing techique of medicinal health-care deer bone glue product |
| 07/28/2004 | CN1515257A Paroxetine control-released composite |
| 07/28/2004 | CN1515256A Application of estrogen antagonist and estrogen excitent for inhibiting pathological disease |
| 07/28/2004 | CN1515252A Application of indole derivative as SHTI excitomotor |